Evidence map›Paper›PMID 30602075›Full record

ArticleGut and liver2019

Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.

Mi Na Kim, Seong Gyu Hwang, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Seung Up Kim, Sang Hoon Ahn

Open access · diamondAbstract readEvaluation StudyMulticenter Study
In one paragraph

Article in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mi Na KimDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Seong Gyu HwangDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Beom Kyung KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jun Yong ParkDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Do Young KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kwang-Hyub HanDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Seung Up KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Sang Hoon AhnDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei University · KRCHA University · KRCHA University Bundang Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis B virus (HBV)-related factors on the risk of HCC development in a cohort with heterogeneous HBV status. Methods: A total of 1,843 patients with CHB from two institutions were included in this study. Ultrasound and laboratory tests, including the α-fetoprotein test, were conducted regularly to detect HCC development. Results: The mean age of our study population (1,063 men and 780 women) was 49.4 years. Cirrhosis was identified in 617 patients (33.5%). During follow-up (median, 42.5 months), 81 patients developed HCC (1.39% per person-year). A total of 645 patients (35.0%) received ongoing AVT at enrollment. Ongoing AVT was not significantly associated with the risk of HCC development (all p>0.05). HBV-related variables (HBV DNA level, hepatitis B e antigen status, and alanine aminotransferase level) were also not significantly associated with the risk of HCC development (all p>0.05). In contrast, cirrhosis was significantly associated with the risk of HCC development, regardless of adjustment (adjusted hazard ratio=4.098 to 7.020; all p<0.05). Cirrhosis significantly predicted the risk of HCC development in subgroups with and without ongoing AVT at enrollment, regardless of adjustment. Conclusions: Our study showed that cirrhosis, not AVT and HBV-related variables, was associated with HCC development in a cohort of patients with heterogeneous HBV status. Our results may help clinicians apply individualized surveillance strategies according to fibrotic status in patients with CHB.

Indexed as

AdultAntiviral AgentsCarcinoma, HepatocellularFemaleHepatitis B, ChronicHepatitis B virusHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesRisk FactorsAntiviral AgentsAntiviral therapyClinical outcomeFibrosisHepatitis BLiver cirrhosis

Identifiers

PMID30602075
PMCPMC6430437
OpenAlexW2906739455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.